# Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

> **NCT03284385** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Locally Advanced Clear Cell Renal Cell Carcinoma
- Locally Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Metastatic Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8

## Interventions

- **DRUG:** Adavosertib

## Key facts

- **NCT ID:** NCT03284385
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-29
- **Primary completion:** 2026-03-01
- **Final completion:** 2027-04-22
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03284385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03284385, "Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03284385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*